These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 31216007)

  • 1. Epigenetic Deregulation of Protocadherin PCDHGC3 in Pheochromocytomas/Paragangliomas Associated With SDHB Mutations.
    Bernardo-Castiñeira C; Valdés N; Celada L; Martinez ASJ; Sáenz-de-Santa-María I; Bayón GF; Fernández AF; Sierra MI; Fraga MF; Astudillo A; Jiménez-Fonseca P; Rial JC; Hevia MÁ; Turienzo E; Bernardo C; Forga L; Tena I; Molina-Garrido MJ; Cacho L; Villabona C; Serrano T; Scola B; Chirivella I; Del Olmo M; Menéndez CL; Navarro E; Tous M; Vallejo A; Athimulam S; Bancos I; Suarez C; Chiara MD
    J Clin Endocrinol Metab; 2019 Nov; 104(11):5673-5692. PubMed ID: 31216007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses.
    Fischer A; Kloos S; Maccio U; Friemel J; Remde H; Fassnacht M; Pamporaki C; Eisenhofer G; Timmers HJLM; Robledo M; Fliedner SMJ; Wang K; Maurer J; Reul A; Zitzmann K; Bechmann N; Žygienė G; Richter S; Hantel C; Vetter D; Lehmann K; Mohr H; Pellegata NS; Ullrich M; Pietzsch J; Ziegler CG; Bornstein SR; Kroiss M; Reincke M; Pacak K; Grossman AB; Beuschlein F; Nölting S
    J Clin Endocrinol Metab; 2023 Sep; 108(10):2676-2685. PubMed ID: 36946182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GIPC2 is an endocrine-specific tumor suppressor gene for both sporadic and hereditary tumors of RET- and SDHB-, but not VHL-associated clusters of pheochromocytoma/paraganglioma.
    Dong Y; Huang Y; Fan C; Wang L; Zhang R; Li W; Guo Z; Wang D; Zheng Z
    Cell Death Dis; 2021 May; 12(5):444. PubMed ID: 33947839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epithelial to mesenchymal transition is activated in metastatic pheochromocytomas and paragangliomas caused by SDHB gene mutations.
    Loriot C; Burnichon N; Gadessaud N; Vescovo L; Amar L; Libé R; Bertherat J; Plouin PF; Jeunemaitre X; Gimenez-Roqueplo AP; Favier J
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E954-62. PubMed ID: 22492777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA expression and SDHB mutations in pheochromocytomas and paragangliomas.
    Li H; Hardin H; Zaeem M; Huang W; Hu R; Lloyd RV
    Ann Diagn Pathol; 2021 Dec; 55():151801. PubMed ID: 34461576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status.
    Eisenhofer G; Lenders JW; Siegert G; Bornstein SR; Friberg P; Milosevic D; Mannelli M; Linehan WM; Adams K; Timmers HJ; Pacak K
    Eur J Cancer; 2012 Jul; 48(11):1739-49. PubMed ID: 22036874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterisation of an Adult Zebrafish Model for
    Miltenburg JB; Gorissen M; van Outersterp I; Versteeg I; Nowak A; Rodenburg RJ; van Herwaarden AE; Olthaar AJ; Kusters B; Conrad C; Timmers HJLM; Dona M
    Int J Mol Sci; 2024 Jul; 25(13):. PubMed ID: 39000369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germline SDHB mutations are common in patients with apparently sporadic sympathetic paragangliomas.
    Klein RD; Jin L; Rumilla K; Young WF; Lloyd RV
    Diagn Mol Pathol; 2008 Jun; 17(2):94-100. PubMed ID: 18382370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
    Hadoux J; Favier J; Scoazec JY; Leboulleux S; Al Ghuzlan A; Caramella C; Déandreis D; Borget I; Loriot C; Chougnet C; Letouzé E; Young J; Amar L; Bertherat J; Libé R; Dumont F; Deschamps F; Schlumberger M; Gimenez-Roqueplo AP; Baudin E
    Int J Cancer; 2014 Dec; 135(11):2711-20. PubMed ID: 24752622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic and epigenetic differences of benign and malignant pheochromocytomas and paragangliomas (PPGLs).
    Khatami F; Mohammadamoli M; Tavangar SM
    Endocr Regul; 2018 Jan; 52(1):41-54. PubMed ID: 29453919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency.
    Richter S; Peitzsch M; Rapizzi E; Lenders JW; Qin N; de Cubas AA; Schiavi F; Rao JU; Beuschlein F; Quinkler M; Timmers HJ; Opocher G; Mannelli M; Pacak K; Robledo M; Eisenhofer G
    J Clin Endocrinol Metab; 2014 Oct; 99(10):3903-11. PubMed ID: 25014000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIF2α supports pro-metastatic behavior in pheochromocytomas/paragangliomas.
    Bechmann N; Moskopp ML; Ullrich M; Calsina B; Wallace PW; Richter S; Friedemann M; Langton K; Fliedner SMJ; Timmers HJLM; Nölting S; Beuschlein F; Fassnacht M; Prejbisz A; Pacak K; Ghayee HK; Bornstein SR; Dieterich P; Pietzsch J; Wielockx B; Robledo M; Qin N; Eisenhofer G
    Endocr Relat Cancer; 2020 Nov; 27(11):625-640. PubMed ID: 33112842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The relationship between clinical characteristics and pathological features in patients with pheochromocytomas/paragangliomas].
    Zhou Y; Zhang WQ; Chen YH; Cui YY; Wang Y; Li TY; Chang XY; Tong AL
    Zhonghua Yi Xue Za Zhi; 2024 Jul; 104(28):2613-2618. PubMed ID: 39019817
    [No Abstract]   [Full Text] [Related]  

  • 14. SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma/paraganglioma.
    Menara M; Oudijk L; Badoual C; Bertherat J; Lepoutre-Lussey C; Amar L; Iturrioz X; Sibony M; Zinzindohoué F; de Krijger R; Gimenez-Roqueplo AP; Favier J
    J Clin Endocrinol Metab; 2015 Feb; 100(2):E287-91. PubMed ID: 25405498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 15 YEARS OF PARAGANGLIOMA: Genetics and mechanism of pheochromocytoma-paraganglioma syndromes characterized by germline SDHB and SDHD mutations.
    Baysal BE; Maher ER
    Endocr Relat Cancer; 2015 Aug; 22(4):T71-82. PubMed ID: 26113606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased expression of Nrf2 and elevated glucose uptake in pheochromocytoma and paraganglioma with SDHB gene mutation.
    Kamai T; Murakami S; Arai K; Nishihara D; Uematsu T; Ishida K; Kijima T
    BMC Cancer; 2022 Mar; 22(1):289. PubMed ID: 35300626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline mutations and genotype-phenotype correlations in patients with apparently sporadic pheochromocytoma/paraganglioma in Korea.
    Kim JH; Seong MW; Lee KE; Choi HJ; Ku EJ; Bae JH; Park SS; Choi SH; Kim SW; Shin C; Kim SY
    Clin Genet; 2014 Nov; 86(5):482-6. PubMed ID: 24134185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and internal validation of a novel predictive model for
    Zhou Y; Gao Y; Ma X; Li T; Cui Y; Wang Y; Li M; Zhang D; Tong A
    Front Endocrinol (Lausanne); 2023; 14():1285631. PubMed ID: 38179299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telomerase Activation and ATRX Mutations Are Independent Risk Factors for Metastatic Pheochromocytoma and Paraganglioma.
    Job S; Draskovic I; Burnichon N; Buffet A; Cros J; Lépine C; Venisse A; Robidel E; Verkarre V; Meatchi T; Sibony M; Amar L; Bertherat J; de Reyniès A; Londoño-Vallejo A; Favier J; Castro-Vega LJ; Gimenez-Roqueplo AP
    Clin Cancer Res; 2019 Jan; 25(2):760-770. PubMed ID: 30301828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Succinate: A Serum Biomarker of SDHB-Mutated Paragangliomas and Pheochromocytomas.
    Lamy C; Tissot H; Faron M; Baudin E; Lamartina L; Pradon C; Al Ghuzlan A; Leboulleux S; Perfettini JL; Paci A; Hadoux J; Broutin S
    J Clin Endocrinol Metab; 2022 Sep; 107(10):2801-2810. PubMed ID: 35948272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.